intelligent, and understands the fact that rare and unforeseen complications can occur. He is willing to take this risk, but he does not understand the long-term lifetime risk of the procedure he is about to undertake. The surgeon has covered the elements of the informed consent process, obtained pre-operative photographs, and feels that the patient understands more hair loss is likely to occur in the future. This case is an example of uniformed consent. The patient cannot understand the consequences of total donor hair depletion, nor appreciate the fact that he will most likely suffer the cosmetic sequela that follows. When will this happen? No answer can be given. What will be the additional cost? Difficult to say. Will the frontal hairline be his major concern by age 40? Perhaps.
{"title":"Notes from the Editor Emeritus, 1999–2001","authors":"D. Stough","doi":"10.33589/33.4.125","DOIUrl":"https://doi.org/10.33589/33.4.125","url":null,"abstract":"intelligent, and understands the fact that rare and unforeseen complications can occur. He is willing to take this risk, but he does not understand the long-term lifetime risk of the procedure he is about to undertake. The surgeon has covered the elements of the informed consent process, obtained pre-operative photographs, and feels that the patient understands more hair loss is likely to occur in the future. This case is an example of uniformed consent. The patient cannot understand the consequences of total donor hair depletion, nor appreciate the fact that he will most likely suffer the cosmetic sequela that follows. When will this happen? No answer can be given. What will be the additional cost? Difficult to say. Will the frontal hairline be his major concern by age 40? Perhaps.","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"48 1","pages":"125 - 125"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88551634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hear from the Assistants","authors":"Marwan Noureldin","doi":"10.33589/33.4.145","DOIUrl":"https://doi.org/10.33589/33.4.145","url":null,"abstract":"","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"14 1","pages":"145 - 145"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72709116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Notable Articles Project","authors":"Luis A. Nader","doi":"10.33589/33.4.134","DOIUrl":"https://doi.org/10.33589/33.4.134","url":null,"abstract":"","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"17 1","pages":"134 - 136"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84957415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"In Loving Memory of Prof. Tamaz Tamazashvili","authors":"Irakli Bebiashvili","doi":"10.33589/33.4.144","DOIUrl":"https://doi.org/10.33589/33.4.144","url":null,"abstract":"","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"130 1","pages":"144 - 144"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78302882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the Editors","authors":"M. Haseeb","doi":"10.33589/33.4.142","DOIUrl":"https://doi.org/10.33589/33.4.142","url":null,"abstract":"","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"4 1","pages":"142 - 142"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86017333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
References 1. Mazzarella GF, et al. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 1997;8(3):189-192. 2. Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatology Venereol. 2021;164(18):2017-2023. 3. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312-1316. 4. Chandrashekar B, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17. 5. Noor NM, et al. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020 Oct 20;12(10):994. 6. Aval MMB, et al. Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study. IET Nanobiotechnol. 2023 Feb;17(1):13-21. n
引用1。Mazzarella GF等。外用非那雄胺治疗雄激素性脱发。16个月疗程后的初步评估。中华皮肤科杂志。1997;8(3):189-192。2. Piraccini BM, et al。局部非那雄胺喷雾溶液治疗男性雄激素性脱发的疗效和安全性:一项III期随机对照临床试验中华皮肤科杂志，2013;32(6):391 - 391。3.3%米诺地尔与3%米诺地尔/0.1%非那雄胺联合治疗男性型脱发的疗效和安全性:一项随机、双盲、比较研究。中华医学杂志，2012;35(3):349 - 349。4. Chandrashekar B, et al。局部米诺地尔加非那雄胺:替代口服非那雄胺后维持毛发密度的研究。中国皮肤科杂志，2015;6(1):17。5. Noor NM，等。月桂酸-壳聚糖低聚物包被度他雄胺纳米脂质载体真皮递送的体外性能。制药学。2020年10月20日,12(10):994。6. 保兑百万桶,et al。抑制毛囊内5- α -毛囊还原酶的杜他雄胺纳米乳制备一项体外研究。生物质化学工程学报，2009;17(1):13-21。n
{"title":"Literature Review","authors":"Guillermo A. Guerrero","doi":"10.33589/33.3.103","DOIUrl":"https://doi.org/10.33589/33.3.103","url":null,"abstract":"References 1. Mazzarella GF, et al. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 1997;8(3):189-192. 2. Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatology Venereol. 2021;164(18):2017-2023. 3. Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312-1316. 4. Chandrashekar B, et al. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17. 5. Noor NM, et al. In vitro performance of dutasteride-nanostructured lipid carriers coated with lauric acid-chitosan oligomer for dermal delivery. Pharmaceutics. 2020 Oct 20;12(10):994. 6. Aval MMB, et al. Dutasteride nanoemulsion preparation to inhibit 5-alpha-hair follicle reductase enzymes in the hair follicle; an ex vivo study. IET Nanobiotechnol. 2023 Feb;17(1):13-21. n","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"67 1","pages":"103 - 103"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79601448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Notes from the Editor Emeritus, 2005–2007","authors":"R. Haber","doi":"10.33589/33.3.89","DOIUrl":"https://doi.org/10.33589/33.3.89","url":null,"abstract":"","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"22 1","pages":"89 - 89"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73644080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND Minoxidil was first introduced in the 1970s as a treatment for refractory hypertension.1 Due to its side-effect profile, its use is reserved for hypertension that has not responded to conventional multidrug regimens.1,2 Tachycardia, fluid retention, and generalized hypertrichosis are minoxidil’s most common adverse effects.2 It was first noted to improve hair loss in male androgenetic alopecia in 1980.3 These observations led to the development of topical minoxidil (TM) as a hair growth agent. It was approved by the United States Food and Drug Administration as a topical treatment for androgenetic alopecia (AGA) in men in 1988 and in women in 1992.4 For several decades, TM has been utilized for AGA. Clinical trials have demonstrated its safety and efficacy in both women and men; however, the clinical response has been variable, and around 50% of patients do not experience any clinical benefit.5,6 Minoxidil is a pro-drug and requires conversion to minoxidil sulfate by the sulfotransferase enzymes to be biologically active.7 Sulfotransferases are xenobiotic metabolizing enzymes expressed in many tissues; when minoxidil is applied to the hair on the scalp, it must be converted by the sulfotransferase present in the hair follicle outer root sheath (ORS).7 The sulfotransferase activity varies among individuals, and a positive association between its activity in the ORS and the clinical response to TM has been found.6,8 However, a lower activity threshold is required to bioactivate oral minoxidil compared with TM.9 This could be because of the liver sulfotransferase’s extensive metabolization of oral minoxidil. As a chronic condition, AGA demands continuous treatment.10 Unfortunately, many patients are poorly compliant with topical therapy due to the resultant undesirable hair texture, scalp irritation, or even the time-consuming nature of having to apply TM repeatedly.11 The usual daily dose of oral minoxidil for hypertension ranges from 10-40 mg/day, and it was not used for alopecia for decades because of its dose-related adverse effects. The use of low-dose oral minoxidil (LDOM; 0.25-5mg/day) for AGA aims to avoid the issues associated with topical application, improve compliance, and enhance clinical response.12 LDOM has been increasingly used for the treatment of AGA. Since Prof. Sinclair’s seminal study, several articles have been published. However, available data is still limited and results mainly from low-evidence studies. Prof. Sinclair evaluated 100 women treated with 0.25mg of minoxidil combined with 25mg of spironolactone for 1 year. He observed a mean reduction in the hair loss clinical scale (ranges from 1 to 5) of 1.3 after 12 months.13
{"title":"Oral Minoxidil for Hair Loss: Update and Perspectives","authors":"P. M. Ramos","doi":"10.33589/33.3.93","DOIUrl":"https://doi.org/10.33589/33.3.93","url":null,"abstract":"BACKGROUND Minoxidil was first introduced in the 1970s as a treatment for refractory hypertension.1 Due to its side-effect profile, its use is reserved for hypertension that has not responded to conventional multidrug regimens.1,2 Tachycardia, fluid retention, and generalized hypertrichosis are minoxidil’s most common adverse effects.2 It was first noted to improve hair loss in male androgenetic alopecia in 1980.3 These observations led to the development of topical minoxidil (TM) as a hair growth agent. It was approved by the United States Food and Drug Administration as a topical treatment for androgenetic alopecia (AGA) in men in 1988 and in women in 1992.4 For several decades, TM has been utilized for AGA. Clinical trials have demonstrated its safety and efficacy in both women and men; however, the clinical response has been variable, and around 50% of patients do not experience any clinical benefit.5,6 Minoxidil is a pro-drug and requires conversion to minoxidil sulfate by the sulfotransferase enzymes to be biologically active.7 Sulfotransferases are xenobiotic metabolizing enzymes expressed in many tissues; when minoxidil is applied to the hair on the scalp, it must be converted by the sulfotransferase present in the hair follicle outer root sheath (ORS).7 The sulfotransferase activity varies among individuals, and a positive association between its activity in the ORS and the clinical response to TM has been found.6,8 However, a lower activity threshold is required to bioactivate oral minoxidil compared with TM.9 This could be because of the liver sulfotransferase’s extensive metabolization of oral minoxidil. As a chronic condition, AGA demands continuous treatment.10 Unfortunately, many patients are poorly compliant with topical therapy due to the resultant undesirable hair texture, scalp irritation, or even the time-consuming nature of having to apply TM repeatedly.11 The usual daily dose of oral minoxidil for hypertension ranges from 10-40 mg/day, and it was not used for alopecia for decades because of its dose-related adverse effects. The use of low-dose oral minoxidil (LDOM; 0.25-5mg/day) for AGA aims to avoid the issues associated with topical application, improve compliance, and enhance clinical response.12 LDOM has been increasingly used for the treatment of AGA. Since Prof. Sinclair’s seminal study, several articles have been published. However, available data is still limited and results mainly from low-evidence studies. Prof. Sinclair evaluated 100 women treated with 0.25mg of minoxidil combined with 25mg of spironolactone for 1 year. He observed a mean reduction in the hair loss clinical scale (ranges from 1 to 5) of 1.3 after 12 months.13","PeriodicalId":14362,"journal":{"name":"International Society of Hair Restoration Surgery","volume":"11 1","pages":"93 - 94"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81532989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：